Virotherapy as Potential Adjunct Therapy for Graft-Vs-Host Disease

Area of Science:

• Oncology
• Virology
• Immunology

Background:

• Graft-versus-host disease (GvHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT).
• Current prevention and treatment strategies for GvHD have limitations.
• Oncolytic viruses are being explored as adjunct therapies in allo-HSCT.

Purpose of the Study:

• To review advances in GvHD prevention and treatment using virotherapy.
• To discuss nonviral adjunct therapies for GvHD in allo-HSCT.
• To evaluate the role of oncolytic viruses in treating hematological cancers and managing GvHD.

Main Methods:

• Review of existing literature on GvHD pathophysiology, risk factors, and therapeutic strategies.
• Analysis of studies investigating oncolytic viruses, specifically myxoma virus (MYXV), for cancer treatment and GvHD prevention.
• Examination of emerging nonviral GvHD therapies.

Main Results:

• Myxoma virus (MYXV) demonstrates oncolytic activity against hematologic malignancies like multiple myeloma and acute myeloid leukemia.
• Ex vivo MYXV treatment of human transplants abrogated GvHD in mice without compromising graft-versus-tumor (GvT) effects.
• MYXV is the first oncolytic virus with demonstrated dual potential in oncolysis and GvHD inhibition.

Conclusions:

• Oncolytic virotherapy, particularly with MYXV, presents a promising adjunct treatment for GvHD.
• Emerging nonviral therapies also offer potential for GvHD management.
• MYXV has a unique dual role in decreasing GvHD while maintaining or enhancing GvT benefits in allo-HSCT.